©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113764
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113764
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113764
Advances in radiofrequency ablation for pancreatic cancer
Si-Yu Peng, Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Zong-Yang Li, Hong-Qiao Cai, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Cai HQ designed the overall concept and outline of the manuscript; Li ZY contributed to the discussion and design of the manuscript; Peng SY contributed to the writing, and editing the manuscript, and review of literature.
Conflict-of-interest statement: The authors have claimed no conflicts.
Corresponding author: Hong-Qiao Cai, MD, PhD, Associate Professor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China.
Received: September 3, 2025
Revised: September 20, 2025
Accepted: November 25, 2025
Published online: January 15, 2026
Processing time: 132 Days and 3.3 Hours
Revised: September 20, 2025
Accepted: November 25, 2025
Published online: January 15, 2026
Processing time: 132 Days and 3.3 Hours
Core Tip
Core Tip: This article highlights the evolving role of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cancer. Advances in energy delivery, probe design, and real-time imaging have enhanced the safety and precision of EUS-RFA. When combined with chemotherapy, EUS-RFA shows promise in improving survival outcomes and symptom control. Moreover, its immunomodulatory effects offer a novel rationale for combination with immunotherapy. Despite encouraging results, further randomized trials and standardization of protocols are needed to establish EUS-RFA as a mainstream component of pancreatic cancer treatment.